VINCENT MED (01612) announced its interim results for the six months ended June 30, 2025. The group achieved revenue of HK$449 million, representing an 18.05% year-on-year increase. Profit attributable to owners of the company reached HK$51.629 million, up 55.1% compared to the same period last year. Basic earnings per share stood at HK$0.0803.

The strong performance in the first half of 2025 was primarily driven by a 28.6% increase in revenue from the imaging disposable products segment. The respiratory products segment returned to growth, with gains sufficient to offset the decline in contributions from the orthopedic support and rehabilitation equipment segment.

Supported by expanded economies of scale, improved operational efficiency, and reduced inventory provisions, gross profit increased by 33.4% to HK$159 million. The gross margin improved from 31.3% to 35.4%.